Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
5.00
+0.05 (1.01%)
At close: Oct 9, 2026, 4:00 PM EDT
5.00
0.00 (0.00%)
Pre-market: Oct 12, 2026, 8:54 AM EDT
Nuvation Bio Revenue
Nuvation Bio had revenue of $31.69M in the quarter ending June 30, 2026, with 555.64% growth. This brings the company's revenue in the last twelve months to $169.90M, up 1,083.56% year-over-year. In the year 2025, Nuvation Bio had annual revenue of $62.90M with 698.96% growth. That makes Nuvation Bio the 18,637th largest company in the world by revenue and 2,986th in the United States.
Revenue (ttm)
$169.90M
Revenue Growth
+1,083.56%
P/S Ratio
10.33
Revenue / Employee
$557,049
Employees
305
Market Cap
1.76B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 62.90M | 55.03M | 698.96% |
| Dec 31, 2024 | 7.87M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| UroGen Pharma | 188.73M |
| Mesoblast | 120.25M |
| Xencor | 104.97M |
| Septerna | 98.88M |
| Intellia Therapeutics | 59.51M |
| Zymeworks | 37.13M |
| Generate Biomedicines | 26.48M |
| Absci | 1.56M |
NUVB News
- 12 days ago - Nuvation Bio initiated with a Buy at Citi - TheFly
- 25 days ago - Nuvation Bio announces FDA approval of sNDA for Ibtrozi - TheFly
- 25 days ago - Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer - PRNewsWire
- 27 days ago - Nuvation Bio’s Ibtrozi shows durable efficacy in NSCLC studies - TheFly
- 27 days ago - Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer - PRNewsWire
- 4 weeks ago - Nuvation Bio Transcript: Cantor Global Healthcare Conference - Transcripts
- 4 weeks ago - Nuvation Bio Transcript: Citigroup’s Biopharma Back to School Summit 2026 - Transcripts
- 5 weeks ago - Nuvation Bio to Participate in Upcoming Investor Conferences - PRNewsWire